BIO-KOREA
BIO KOREA 2024, jointly held by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), has commenced its registration for Business Partnering on March 4, 2024 (Mon.).
Business Partnering, one of the major programs at BIO KOREA, provides opportunities for one-on-one meetings between companies at home and abroad, alongside pertinent institutions within the BioHealth sector. This business matchmaking will foster discussions on potential business and research collaborations, encompassing collaborative research, market entry, and technology transfers.
In 2023, the easing of COVID-19 restrictions has led to increased participation. As many as 782 companies from 51 countries attended on-site events and 1,320 business meetings were arranged. This year, the Business Partnering Center will be expanded to provide more opportunities for participating companies to make business connections.
Throughout the three-day event from May 8 (Wed.) to May 10 (Fri.), the Business Partnering will unfold both online and offline on the sidelines of BIO KOREA 2024. In particular, online meetings will be supported round-the-clock to guarantee seamless engagements with international counterparts.
Companies seeking to engage in the Business Partnering should register through either the FCA or OPA options. Those pre-registering with the FCA by April 30 (Tue.), will receive a 10% discount.
* FCA (Full Convention Access): Grants in-person participation across all programs, including conferences, exhibitions, and Business Partnering, for the three-day event.
* OPA (Online Partnering Access): Provides access to online business partnering activities over the three-day event.
Meanwhile, due to an overwhelming response from domestic and overseas entities, applications for participation in the fair have closed earlier than anticipated.
This year, at least 50 foreign companies and research institutions are expected to be present with delegations from Business Sweden in Seoul, the Danish Embassy in Korea, Austrade, and Biocom California in the USA. Furthermore, a heightened presence of local enterprises from various countries, such as Germany, Thailand, and Taiwan, is expected to explore commercial prospects with Korean companies, given their participation in the national pavilion booths.
Participants include major domestic and foreign companies, including ST Pharm, Yuhan Corporation, Lonza, Wuxi Apptech, Fujifilm, and Labcorp. Exhibition booths for advanced regenerative medicine companies, including a Special Hall for AI featuring digital healthcare companies, will be opened as well.
More information is available on the BIO KOREA 2024 website (www.biokorea.org). Companies interested in Business Partnering can register via the website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311710731/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Planet Awarded €240 Million Satellite Services Deal1.7.2025 15:03:00 CEST | Press release
Planet Labs Germany GmbH, a leading provider of daily data and insights about Earth, today announced a multi-year €240 million agreement, funded by the German government, in support of European peace and security. Through the agreement, Planet will provide dedicated capacity and direct downlink services on Pelican satellites over specific European regions. This deal also includes access to PlanetScope and SkySat data, along with AI-enabled solutions for enhanced situational awareness and maritime domain awareness. The contract will provide high-resolution imagery and timely intelligence via dedicated capacity on Pelican satellites, including those being built for our previously announced satellite services agreement. This satellite services ‘dedicated capacity’ model offers a cost-effective and efficient way for customers to gain access to advanced space-based capabilities without the operational complexities of building and maintaining their own satellite infrastructure. “We are incre
Esports World Cup Foundation and Lenovo™ Partner to Power the Next Generation of Esports Champions1.7.2025 15:00:00 CEST | Press release
Lenovo’s Legion premium gaming brand joins the world’s largest esports event to fuel elite performance and elevate the fan experience through world-class hardware.[Media Kit] The Esports World Cup Foundation (EWCF) and Lenovo today announced a partnership to make Lenovo’s Legion brand of gaming devices the Official PC & Gaming Hardware partner of the Esports World Cup 2025 (EWC). Lenovo Legion is the one of the world’s leading gaming ecosystem brands, and will be bring its relentless commitment to innovation and performance to the global stage, empowering EWC athletes to compete at their highest level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626760677/en/ From training rooms to tournament zones, EWC athletes will be equipped with Lenovo Legion Towers, Lenovo Legion laptops, and peripherals – built for elite esports play with advanced thermal systems, high-performance silicon, high refresh-rate displays and low late
Citigroup Announces €1.75 Billion Redemption of 1.250% Fixed Rate/Floating Rate Notes Due 20261.7.2025 14:30:00 CEST | Press release
Citigroup Inc. is announcing the redemption, in whole, constituting €1,750,000,000 of its 1.250% Fixed Rate/Floating Rate Notes due 2026 (the “notes”) (ISIN: XS2167003685). The redemption date for the notes is July 6, 2025 (the “redemption date”). The cash redemption price for the notes payable on the redemption date will equal par plus accrued and unpaid interest, to but excluding, the redemption date and will be paid on July 7, 2025, the next succeeding business day after the redemption date. The redemption announced today is consistent with Citigroup's liability management strategy and reflects its ongoing efforts to enhance the efficiency of its funding and capital structure. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, including without limitation, the economic value, regulatory changes, potential impact on Citigroup's net interest margin and borrowing costs, the overall remaining tenor of Citigroup's debt portfoli
LevelBlue to Acquire Trustwave, Becoming Largest Pure-Play Managed Security Services Provider1.7.2025 14:00:00 CEST | Press release
LevelBlue Strengthens Market-Leading Managed Detection and Response Services with Advanced AI Capabilities, While Adding Prestigious FedRAMP and StateRAMP Authorizations LevelBlue, a global leader in cloud-based, AI-driven managed security services (MSS), has signed a definitive agreement to acquire Trustwave, a global provider of cybersecurity and managed detection and response (MDR) services from the MC2 Security Fund (MC2), a private equity fund sponsored by The Chertoff Group, an internationally recognized security and growth advisory firm. This strategic acquisition complements LevelBlue’s recent agreement to acquire Aon’s cybersecurity consulting business, formerly known as Stroz Friedberg, and further strengthens the company’s market leadership, uniting two leading Managed Security Service Providers (MSSPs) to deliver unparalleled cybersecurity outcomes through a comprehensive and expanded suite of services designed to stay ahead of the rapidly evolving threat landscape. The acq
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis1.7.2025 13:34:00 CEST | Press release
- ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride, demonstrating greater improvement in CFTR function -- Approximately 31,000 people with CF in the EU are now eligible for this new highly effective modulator therapy - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom